Annual Report Details Take-Private Offer, Mixed Financials, and Regulatory Headwinds

summarizeSummary

Annual report discloses a non-binding take-private offer, mixed financial results with strong income from continuing operations but declining Adjusted EBITDA, and significant regulatory and litigation risks.

check_boxKey Events

• Executive Chairman Proposes Take-Private Transaction

  On November 24, 2025, Executive Chairman Robert A. Ortenzio made a non-binding offer to acquire all outstanding shares for $16.00 to $16.20 per share. An independent special committee is currently reviewing the proposal and other strategic alternatives.

• Mixed Financial Performance in 2025

  Revenue increased 5.1% to $5.45 billion, and income from continuing operations, net of tax, rose significantly to $214.5 million from $129.9 million in 2024. However, Adjusted EBITDA decreased by 3.4% to $493.2 million, and Adjusted EBITDA margin declined to 9.0% from 9.8%.

• Significant Regulatory Changes and Risks

  The 'One Big Beautiful Bill Act' (OBBBA) is projected to reduce federal Medicaid funding by $1 trillion over 10 years, potentially decreasing future reimbursements. Additionally, changes to LTCH outlier reconciliation criteria (20% CCR change threshold) and a decrease in the site-neutral payment rate's fixed-loss amount for LTCHs increase the likelihood of Medicare payment recoupments.

• Ongoing Litigation Regarding Billing Practices

  The company is subject to an ongoing DOJ investigation and a qui tam lawsuit related to alleged billing fraud for physical therapy services, with an uncertain outcome.

auto_awesomeAnalysis

This annual report highlights a significant non-binding take-private offer from the Executive Chairman, which could materially impact the company's future and stock value. While income from continuing operations saw substantial growth, Adjusted EBITDA declined, indicating some operational pressures. The company also faces notable regulatory changes, particularly the 'One Big Beautiful Bill Act' impacting Medicaid funding and stricter LTCH outlier payment reconciliation criteria, which could negatively affect future reimbursements. Ongoing litigation related to billing practices adds further risk. Investors should closely monitor developments regarding the take-private proposal and the evolving regulatory landscape.